To the full analysis
Buyback calculator for Ionis Pharmaceuticals
Ionis Pharmaceuticals stock: key metrics
IONSIonis Pharmaceuticals had an operating margin of −40.5% and a return on invested capital (ROIC) of −10.2% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 0.0% | −438.9% | −308.9% |
| 2007 | 0.0% | −56.4% | no data |
| 2008 | 100.0% | −12.2% | no data |
| 2009 | 100.0% | −22.6% | no data |
| 2010 | 100.0% | −44.6% | −56.5% |
| 2011 | 100.0% | −71.8% | −85.6% |
| 2012 | −55.3% | −67.5% | −64.2% |
| 2013 | −25.0% | −35.1% | −41.2% |
| 2014 | −12.9% | −22.3% | −18.2% |
| 2015 | −13.6% | −26.7% | −31.1% |
| 2016 | 100.0% | −5.4% | −16.2% |
| 2017 | 100.0% | 6.0% | 0.1% |
| 2018 | 99.7% | −10.2% | 45.6% |
| 2019 | 99.6% | 32.6% | 24.8% |
| 2020 | 98.4% | −23.6% | −60.9% |
| 2021 | 98.7% | −3.7% | −3.5% |
| 2022 | 97.6% | −69.8% | −45.9% |
| 2023 | 98.8% | −44.9% | −46.5% |
| 2024 | 98.4% | −67.4% | −64.4% |
| 2025 | 98.3% | −40.5% | −40.4% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −67.0% | −21.6% | −17.9% |
| 2007 | no data | −11.8% | no data |
| 2008 | no data | −3.1% | no data |
| 2009 | no data | −4.3% | no data |
| 2010 | −25.0% | −7.6% | −11.1% |
| 2011 | −49.5% | −13.0% | −17.5% |
| 2012 | −35.8% | −12.3% | −12.0% |
| 2013 | −16.0% | −6.6% | −7.2% |
| 2014 | −15.1% | −4.7% | −4.1% |
| 2015 | −44.0% | −7.2% | −9.3% |
| 2016 | −60.7% | −2.0% | −6.6% |
| 2017 | 0.1% | 2.6% | 0.0% |
| 2018 | 26.1% | −2.8% | 10.3% |
| 2019 | 18.9% | 11.6% | 8.6% |
| 2020 | −59.8% | −5.4% | −18.6% |
| 2021 | −3.7% | −1.1% | −1.1% |
| 2022 | −47.1% | −14.1% | −10.6% |
| 2023 | −94.7% | −11.6% | −12.3% |
| 2024 | −77.1% | −14.2% | −15.1% |
| 2025 | −77.9% | −10.2% | −10.8% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 28 Feb 2021)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.